---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-012308"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-05-06T23:59:59+00:00"
generated_at: "2026-06-25T23:13:19.195719+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oncotelic appoints CMO Fatih Uckun and CRO Seymour Fein effective May 1, 2022

## Summary
- Fatih Uckun appointed Consulting CMO; $504k/year salary, 70% time commitment.
- Seymour Fein appointed Consulting Chief Regulatory Officer; $180k/year, 10% time.
- Both to lead OT-101 registration trials for DIPG and pancreatic cancer under joint venture.
- Uckun previously CMO at Reven, Ares, Aptevo; Fein has 35+ years and 20+ FDA approvals.

## SEC filing metadata
- accession: 0001493152-22-012308
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-05-06T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-012308
- JSON: https://secwatch.observer/filing/0001493152-22-012308.json
- Plain text: https://secwatch.observer/filing/0001493152-22-012308.txt

## Key facts
- Executive change
  Fatih Uckun was appointed as Consulting Chief Medical Officer at Oncotelic Therapeutics, Inc..
  - Action: appointed
  - Role: Consulting Chief Medical Officer
  source text: On May 1, 2022, Oncotelic Therapeutics, Inc. (the “ Company ”) appointed Fatih Uckun, M.D., Ph.D. as its Consulting Chief Medical Officer for the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm
- Executive change
  Seymour Fein was appointed as Consulting Chief Regulatory Officer at Oncotelic Therapeutics, Inc..
  - Action: appointed
  - Role: Consulting Chief Regulatory Officer
  source text: In addition, on May 1, 2022, the Company appointed Dr. Seymour Fein as its Consulting Chief Regulatory Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315222012308/0001493152-22-012308-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.